US2009158449A1PendingUtilityA1

Transgenic avian which has foreign gene containing sequence encoding feline-derived protein and method for production thereof

46
Assignee: KANEKA CORPPriority: Aug 31, 2005Filed: Aug 30, 2006Published: Jun 18, 2009
Est. expiryAug 31, 2025(expired)· nominal 20-yr term from priority
Inventors:Tomoyuki NakaishiTakuya ShindoTomoko Awa
A01K 2267/02A61K 38/1816C12N 2830/008A61K 38/00C07K 14/005A01K 67/0275A61K 47/60A01K 2267/01C12N 2015/8518C12N 2799/027A61P 7/06C12N 15/86C07K 14/505C12N 2760/20222C12N 7/00C12N 2740/10043A01K 2217/05C12N 15/8509A01K 2227/30A01K 2217/052C12N 2740/10052
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention has for its object to provide a transgenic bird with a foreign gene containing a feline-derived protein-encoding sequence as transferred therein, and a method of producing the same. The present invention provides a method of producing a feline-derived protein by using a transgenic bird with a method which comprises infecting an avian embryo with a replication defective retrovirus vector containing a foreign gene by microinjection thereof into the early heart or blood vessel formed in the embryo and allowing the embryo to hatch.

Claims

exact text as granted — not AI-modified
1 . A transgenic bird
 which has a foreign gene containing a sequence encoding a feline-derived protein.   
     
     
         2 . A transgenic bird
 which has a foreign gene containing a sequence encoding a feline-derived cytokine protein and/or a protein substantially identical in biological activity thereto.   
     
     
         3 . A transgenic bird
 which has a foreign gene containing at least a part of a sequence encoding the feline-derived erythropoietin identified under SEQ ID NO:1 in the sequence listing and/or a protein substantially identical in biological activity thereto.   
     
     
         4 . A transgenic bird
 which has a foreign gene containing a sequence encoding the feline-derived erythropoietin identified under SEQ ID NO:1 in the sequence listing and/or a protein substantially identical in biological activity thereto.   
     
     
         5 . The transgenic bird according to  claim 1 , which is produced by using a replication defective retrovirus vector. 
     
     
         6 . The transgenic bird according to  claim 5 ,
 wherein the replication defective retrovirus vector contains a sequence derived from Moloney murine leukemia virus and/or Moloney murine sarcoma virus.   
     
     
         7 . The transgenic bird according to  claim 5 ,
 wherein the replication defective retrovirus vector contains a sequence derived from murine stem cell virus.   
     
     
         8 . The transgenic bird according to  claim 5 ,
 wherein the replication defective retrovirus vector contains the VSV-G envelope sequence.   
     
     
         9 . The transgenic bird according to  claim 5 ,
 which is produced by using a replication defective retrovirus vector containing a non-tissue-specific promoter gene.   
     
     
         10 . The transgenic bird according to  claim 9 ,
 wherein the non-tissue-specific promoter gene contains a part or the whole of the chicken β-actin promoter gene.   
     
     
         11 . The transgenic bird according to  claim 1 ,
 which is produced by using a replication defective retrovirus vector containing a tissue-specific promoter gene.   
     
     
         12 . The transgenic bird according to  claim 11 ,
 wherein the tissue-specific promoter gene contains a part or the whole of an oviduct-specific promoter gene.   
     
     
         13 . The transgenic bird according to  claim 12 ,
 wherein the oviduct-specific promoter gene contains at least a part or the whole of the ovalbumin, ovotransferrin, ovomucoid, ovomutin, lysozyme, G2 globulin, G3 globulin, ovoinhibitor, ovoglycoprotein, ovoflavoprotein, ovomacroglobulin, cystatin or avidin promoter gene or a combination thereof.   
     
     
         14 . The transgenic bird according to  claim 1 ,
 which is produced by using a replication defective retrovirus vector containing a transcription enhancer and/or a regulatory element.   
     
     
         15 . The transgenic bird according to  claim 14 ,
 wherein the regulatory element contains a part or the whole of the woodchuck posttranscriptional regulatory element sequence.   
     
     
         16 . The transgenic bird according to  claim 1 ,
 which is obtained by a method comprising infecting an avian embryo with a replication defective retrovirus vector containing a foreign gene and allowing the embryo to hatch.   
     
     
         17 . The transgenic bird according to  claim 16   which is obtained by a method comprising incubating a fertilized avian egg, infecting the embryo thereof after the lapse of at least 24 hours following the start of incubation with a replication defective retrovirus vector containing a foreign gene and allowing the embryo to hatch.   
     
     
         18 . The transgenic bird according to  claim 17 ,
 wherein the embryo is one formed during the period not earlier than 32 hours and not later than 72 hours after the start of incubation.   
     
     
         19 . The transgenic bird according to  claim 18 ,
 wherein the embryo is one formed during the period not earlier than 48 hours and not later than 64 hours after the start of incubation.   
     
     
         20 . The transgenic bird according to  claim 16 ,
 which is obtained by a method comprising infecting the embryo with the replication defective retrovirus vector by microinjection thereof into the heart or blood vessel formed in the embryo.   
     
     
         21 . The transgenic bird according to  claim 1 ,
 wherein said bird is a poultry bird.   
     
     
         22 . The transgenic bird according to  claim 21 ,
 wherein said bird is a chicken.   
     
     
         23 . The transgenic bird according to  claim 1 , a descendant thereof, an egg thereof and spermatozoa thereof. 
     
     
         24 . A method of producing the transgenic bird according to  claim 1 ,
 which comprises infecting an avian embryo with a replication defective retrovirus vector containing a foreign gene and allowing the embryo to hatch.   
     
     
         25 . A method of producing a feline-derived protein
 which comprises any or a combination of extracting the protein from the blood and/or somatic cells of the transgenic bird according to  claim 1  and/or an egg laid thereby, purifying and activating the same.   
     
     
         26 . A polyethylene glycol-modified feline-derived protein
 which is obtained by chemically modifying a feline-derived protein produced by the method according to  claim 25  with polyethylene glycol.   
     
     
         27 . The polyethylene glycol-modified feline-derived protein according to  claim 26 ,
 wherein the feline-derived protein comprises a feline-derived cytokine protein and/or a protein substantially identical in biological activity thereto.   
     
     
         28 . The polyethylene glycol-modified feline-derived protein according to  claim 26 ,
 wherein the feline-derived protein is a protein containing at least a part of feline-derived erythropoietin identified under SEQ ID NO: 1 in the sequence listing and/or of a protein substantially identical in biological activity thereto.   
     
     
         29 . The polyethylene glycol-modified feline-derived protein according to  claim 26 ,
 wherein the feline-derived protein comprises feline-derived erythropoietin identified under SEQ ID NO: 1 in the sequence listing and/or a protein substantially identical in biological activity thereto.   
     
     
         30 . The polyethylene glycol-modified feline-derived protein according to  claim 1 ,
 wherein the polyethylene glycol used for the modification of the feline-derived protein has a weight average molecular weight of 5 to 40 kDa.   
     
     
         31 . The polyethylene glycol-modified feline-derived protein according to  claim 30 ,
 wherein the weight average molecular weight of the polyethylene glycol is 20 kDa.   
     
     
         32 . The polyethylene glycol-modified feline-derived protein according to  claim 26 ,
 wherein the number of polyethylene glycol molecules added is 1 or 2 or more and the apparent molecular weight, per polyethylene glycol-modified molecule, is from 100 kDa to 900 kDa as determined by gel filtration column chromatography in an aqueous solvent.   
     
     
         33 . The polyethylene glycol-modified feline-derived protein according to  claim 32 ,
 wherein the number of polyethylene glycol molecules added is 1 and the apparent molecular weight, per polyethylene glycol-modified molecule, is from 100 kDa to 500 kDa as determined by gel filtration column chromatography in an aqueous solvent.   
     
     
         34 . A polyethylene glycol-modified feline-derived protein composition
 which comprises the polyethylene glycol-modified feline-derived protein according to  claim 32 .   
     
     
         35 . A medicinal composition for feline use
 which comprises, as an active ingredient, the polyethylene glycol-modified feline-derived protein according to  claim 26 .   
     
     
         36 . A medicinal composition for feline use
 which comprises, as an active ingredient, the polyethylene glycol-modified feline-derived protein composition according to  claim 34 .   
     
     
         37 . The medicinal composition according to  claim 35   which has feline erythropoietin activity and prolonged drug efficacy and is intended for use in the treatment of feline renal anemia.   
     
     
         38 . A method of producing the polyethylene glycol-modified feline-derived protein composition according to  claim 34   which comprises causing a succinimidyl ester derivative of polyethylene glycol to add to a feline-derived protein.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.